Reset Pharma
New York, US · Founded 2020 · 2 known investors
Reset Pharma is a CNS-focused pharmaceutical company developing psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases. It holds an exclusive worldwide license from NYU Langone Health for related intellectual property.
Founders & leadership
JA
John AndreadisNamed on SEC filing
JK
Jan-Anders KarlssonNamed on SEC filing
PT
Philip TaubNamed on SEC filing
TS
Tim SchlidtNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$11.1M disclosed across 1 round · 2021
▶$11.1MraisedFeb 2022 · 26 investors · PharmaceuticalsRule 506(b)
▶$11.1MraisedFeb 2022 · 26 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John AndreadisExecutive Officer, Director
- Jan-Anders KarlssonExecutive Officer, Director
- Philip TaubDirector
- Tim SchlidtDirector
- Offering amount
- $12.7M
- Amount sold
- $11.1M
- Minimum investment
- $25K
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapResponse Pharmaceuticals5 shared keywordsResponse Pharmaceuticals is a clinical-stage drug developer working on RDX-002, a small-molecule iMTP inhibitor for weight management and metabolic health, including post-GLP-1 receptor agonist weight management and antipsychotic-induced weight gain. The company is advancing the candidate through Phase 2 clinical trials.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Sarepta Therapeutics3 shared keywordsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Transcend Therapeutics3 shared keywordsTranscend Therapeutics develops rapid-acting pharmaceutical treatments for neuropsychiatric diseases, including PTSD and depression, targeting patients unresponsive to current psychiatric medications. The company is a clinical-stage biotech firm focused on neuroscience-based drug development.
Risetherapeutics3 shared keywordsRise Therapeutics develops oral immunotherapies, called Oral Immune BioModulators, using a synthetic biology-based drug design approach to treat autoimmune diseases and cancer. The company combines immunology research with in-house clinical GMP manufacturing and regulatory expertise to advance its pipeline through clinical validation.
Companies competing with Reset Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Reset Pharma do?
- Reset Pharma is a CNS-focused pharmaceutical company developing psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases. It holds an exclusive worldwide license from NYU Langone Health for related intellectual property.
- Who are Reset Pharma's investors?
- Reset Pharma's investors include Iter Investments, PsyMed Ventures.
- How much funding has Reset Pharma raised?
- Reset Pharma has disclosed $11.1M raised across 1 round.
- Where is Reset Pharma headquartered?
- Reset Pharma is headquartered in New York, US.